profile main - At a glance

Noven at a Glance

(As of February 1, 2010)

Core Business:	Specialty pharmaceutical company engaged in the research, development, manufacture, marketing and sale of prescription pharmaceutical products.	Vivelle-Dot^®, the most prescribed transdermal estrogen therapy product in the U.S., developed and manufactured by Noven
Year of Incorporation:	1987
Locations:	Noven Pharmaceuticals, Inc. Florida: 11960 SW 144th Street Miami, FL 33186 Tel: 305-253-5099 New York: 405 Lexington Avenue 59th Floor New York, NY 10174 Tel: 212-682-4420 California: 2730 Loker Avenue W. Carlsbad, CA 92010 Tel: 760-431-4670 New Jersey: 100 Campus Drive Florham Park, NJ 07932-1006 Tel: 973-765-0122
President & Chief Executive Officer:	Jeffrey F. Eisenberg
Vice President & Chief Financial Officer:	Michael D. Price
Media and General Business Inquiries:	Joseph C. Jones Vice President – Corporate Affairs Tel: 305-253-1916 jjones@noven.com
Licensing and Business Development Inquiries:	Patrick Gallagher Vice President – Business Development Tel: 212-287-0968 pgallagher@noven.com
Affiliated Companies:	Parent Company: Noven is an indirect wholly-owned subsidiary of Hisamitsu Co., Inc. Novogyne Pharmaceuticals – a women’s health products company jointly owned by Noven and Novartis Pharmaceuticals Corporation Noven Therapeutics, LLC – Noven's specialty pharmaceutical marketing and sales company
Employees:	Approximately 650
Key Products:	Vivelle-Dot^®(estradiol transdermal system) World’s Smallest Transdermal Estrogen Patch (U.S. & Canada) Marketed by Novogyne Pharmaceuticals CombiPatch^®(estradiol/norethindrone acetate) Combination Estrogen/Progestogen Patch (U.S.) Marketed by Novogyne Pharmaceuticals Estradot^®(estradiol transdermal system) World's Smallest Transdermal Estrogen Patch (Europe & elsewhere) Marketed by Novartis Estalis^®(estradiol/norethindrone acetate) Combination Estrogen/Progestogen Patch (Europe & elsewhere) Marketed by Novartis Stavzor^®(valproic acid) Delayed Release Capsules Marketed by Noven Therapeutics, LLC Pexeva^®(paroxetine mesylate) Selective Serotonin Reuptake Inhibitor (SSRI) Marketed by Noven Therapeutics, LLC Lithobid^®(lithium carbonate) Extended Release Lithium (U.S.) Marketed by Noven Therapeutics, LLC Daytrana^®(methylphenidate transdermal system) Once-daily Transdermal Methylphenidate Patch (U.S.) Marketed by Shire plc
Research & Development:	A non-hormonal oral product (Mesafem™) in development for menopausal hot flashes, and a range of transdermal drug delivery systems in development for women's health, central nervous system disorders and other therapeutic areas, including an amphetamine patch for ADHD, and transdermal development collaborations with Hisamitsu.
Patient, Physician and Pharmacist Inquiries Regarding Stavzor^®, Pexeva^®and Lithobid^®:	Kendle International, Inc. 441 Vine Street Suite 1200 Cincinnati, Ohio 45202 Attn: Safety Department Tel: 800-455-8070
Patient, Physician and Pharmacist Inquiries Regarding, Vivelle-Dot^®or CombiPatch^®:	Customer Interaction Center Novartis Pharmaceuticals Corporation One Health Plaza Building 122 East Hanover, New Jersey 07936 Tel: 888-669-6682 Fax: 973-781-3115 Click here for E-mail Contact
Patient, Physician and Pharmacist Inquiries Regarding Daytrana^®:	Shire US Inc. 725 Chesterbrook Blvd. Wayne, PA 19087 Tel: 800-828-2088